NCT03358407View on ClinicalTrials.gov

GSK2983559 First Time in Human Study

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 11, 2018

Primary Completion Date

February 19, 2019

Study Completion Date

February 19, 2019

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

GSK2983559

GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.

DRUG

Placebo

Placebo oral capsules matching GSK2983559 will be available for subjects.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03358407 - GSK2983559 First Time in Human Study | Biotech Hunter | Biotech Hunter